GIKLY Stock - Grifols, S.A.
Unlock GoAI Insights for GIKLY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $7.21B | $6.59B | $6.06B | $4.93B | $5.34B |
| Gross Profit | $2.79B | $2.49B | $2.21B | $1.96B | $2.26B |
| Gross Margin | 38.7% | 37.8% | 36.5% | 39.8% | 42.2% |
| Operating Income | $1.19B | $799.40M | $782.44M | $595.06M | $996.13M |
| Net Income | $156.92M | $59.31M | $208.28M | $188.73M | $618.55M |
| Net Margin | 2.2% | 0.9% | 3.4% | 3.8% | 11.6% |
| EPS | $0.12 | $0.04 | $0.16 | $0.14 | $0.45 |
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Visit WebsiteEarnings History & Surprises
GIKLYEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Feb 24, 2026 | — | — | — | — |
Q4 2025 | Nov 4, 2025 | $0.12 | $0.11 | -9.5% | ✗ MISS |
Q3 2025 | Aug 1, 2025 | $0.11 | $0.10 | -11.3% | ✗ MISS |
Q2 2025 | May 12, 2025 | $0.07 | $0.10 | +29.2% | ✓ BEAT |
Q1 2025 | Feb 26, 2025 | $0.12 | $0.05 | -54.7% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $0.11 | $0.04 | -61.4% | ✗ MISS |
Q3 2024 | Jul 30, 2024 | $0.07 | $0.01 | -83.9% | ✗ MISS |
Q2 2024 | May 14, 2024 | $0.05 | $0.05 | -14.3% | ✗ MISS |
Q1 2024 | Mar 31, 2024 | — | $0.02 | — | — |
Q3 2023 | Sep 30, 2023 | $0.10 | $0.05 | -54.7% | ✗ MISS |
Q2 2023 | Jun 30, 2023 | $0.10 | $0.05 | -51.6% | ✗ MISS |
Q2 2023 | Apr 18, 2023 | $0.08 | $0.02 | -80.0% | ✗ MISS |
Q1 2023 | Mar 31, 2023 | — | $-0.01 | — | — |
Q3 2022 | Sep 30, 2022 | — | $0.03 | — | — |
Q2 2022 | Jun 30, 2022 | $0.15 | $0.07 | -53.6% | ✗ MISS |
Q2 2022 | Apr 29, 2022 | — | $-0.03 | — | — |
Q1 2022 | Mar 31, 2022 | — | $0.04 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.03 | — | — |
Q2 2021 | Jun 30, 2021 | — | $0.12 | — | — |
Latest News
Frequently Asked Questions about GIKLY
What is GIKLY's current stock price?
What is the analyst price target for GIKLY?
What sector is Grifols, S.A. in?
What is GIKLY's market cap?
Does GIKLY pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to GIKLY for comparison